
Jan 30, 2025, 11:56
Emirates Oncology Society – The exploratory biomarker analysis of the Phase 3 KEYNOTE-522 study
Emirates Oncology Society shared on LinkedIn:
“Join EOS for an insightful session with Dr. Aref Chehal, as he presents the exploratory biomarker analysis of the Phase 3 KEYNOTE-522 study on neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer (TNBC) during the Best of SABCS UAE!
Date: Saturday, February 8, 2025
Location: Anantara, Downtown Dubai, UAE
Register now!
Find the Registration link in the BIO.
This exclusive event by EOS and Emirates Breast Cancer Working Group!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 26, 2025, 15:47
Feb 26, 2025, 15:38
Feb 26, 2025, 15:34
Feb 26, 2025, 15:33
Feb 26, 2025, 15:22
Feb 26, 2025, 15:16
Feb 26, 2025, 14:04
Feb 26, 2025, 13:37